-
Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer
01 Aug 2025 23:05 GMT
… shape the metastatic breast cancer treatment paradigm, particularly … “Unfortunately, ER-positive breast cancer is still considered incurable … exemestane [Aromasin], and anastrozole [Armidex], the cancer … advanced-or-metastatic-breast-cancer
FDA approves …
-
Late Breast Cancer Recurrence Prediction: The Role of CTS5 and Progesterone Receptor Status
28 Jul 2025 09:40 GMT
… validated using data from the Arimidex, Tamoxifen, Alone or … with a second primary breast tumor or HER2-positive disease … of cases (142 patients), anastrozole in 6.2% (10 … early oestrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2021;186 …
-
Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review
30 Jun 2025 09:58 GMT
… inhibitors (letrozole or anastrozole) versus placebo … breast cancer therapy. Given the variations in breast cancer … amplification in 2305 breast tumours. Breast Cancer Res. 2019;21 … breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer …
-
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
26 Jun 2025 23:48 GMT
… a history of breast cancer. Breast cancer and CVD share … letrozole, anastrozole, exemestane). More than 80% of breast cancers are hormone … 1).45 The Arimidex and Tamoxifen Alone or … venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. …
-
21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
26 Jun 2025 23:48 GMT
… +)/HER2-negative (HER2–) early breast cancer (EBC). In an analysis with … 3 years) plus an NSAI (anastrozole 1 mg/day or …
-
June Breast Cancer Highlights: Top 5 Updates Patients Should Know
25 Jun 2025 21:25 GMT
… with letrozole or anastrozole lowered the chance of … Winship Cancer Institute.
Breast Cancer Biomarkers Drives Patient Treatment … positive advanced or metastatic breast cancer. This investigation evaluated … ER+, HER2- advanced breast cancer (ABC) treated with …
-
ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer
05 Jun 2025 19:27 GMT
… negative (HER2-) advanced breast cancer. These findings, which … with an aromatase inhibitor (anastrozole [Arimidex; AstraZeneca] or letrozole … clinical paradigm in breast cancer. Camizestrant is the … treatment of HR+ breast cancer,” Susan Galbraith, executive …
-
Kisqali Benefit Lasts Across Age in Breast Cancer Subset
03 Jun 2025 20:54 GMT
… positive, HER2-negative early breast cancer, Kisqali (ribociclib) plus … regimen with letrozole or anastrozole (1115 patients) versus … which no invasive breast cancer returns or spreads. … stop hormone receptor–positive breast cancer.
ECOG performance status …
-
Switching to Camizestrant After Detection of ESR1 Mutation Improves Progression-Free Survival for Some Breast Cancer Patients
03 Jun 2025 14:58 GMT
… positive, HER2-negative advanced breast cancer, according to research … HER2-negative advanced breast cancer often receive hormone therapy … -sensitive HR-positive breast cancer develop ESR1 mutations … aromatase inhibitor (letrozole or anastrozole) and a CDK4…
-
Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer
03 Jun 2025 12:31 GMT
… incidence of early onset breast cancer increases, it is … aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin … as a treatment for breast cancer by regulatory authorities … HR+/HER2- advanced breast cancer. Further, Kisqali in combination …
About
© 1995-2025